Tsutomu Takeuchi

Jun 1, 2024 | jrheum.org | Tsutomu Takeuchi |Naoko Wakasugi |Tetsuji Hashida |Satoshi Uno

Key Indexing Terms: immunosuppressive agent lupus nephritis postmarketing product surveillance Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease, predominantly affecting women of reproductive age.1,2 Asian populations are also disproportionately affected,1-3 with a reported prevalence of SLE in Japan of up to 38 per 100,000.3 SLE has a heterogeneous presentation, with clinical manifestations ranging from skin rashes to major organ involvement.1 Lupus nephritis...

May 28, 2024 | nature.com | Jun Inamo |Mahoko Takahashi Ueda |Hiroshi Nishida |Tsutomu Takeuchi |Kazuyoshi Ishigaki |Yasushi Ishihama

AbstractAlternative splicing events are a major causal mechanism for complex traits, but they have been understudied due to the limitation of short-read sequencing. Here, we generate a full-length isoform annotation of human immune cells from an individual by long-read sequencing for 29 cell subsets. This contains a number of unannotated transcripts and isoforms such as a read-through transcript of TOMM40-APOE in the Alzheimer’s disease locus.

Feb 9, 2024 | jrheum.org | Tsutomu Takeuchi |Naoko Wakasugi |Satoshi Uno |Tetsuji Hashida

Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis in Japan: 10-year analysis of the real-world TRUST study Tsutomu Takeuchi, Naoko Wakasugi, Tetsuji Hashida, Satoshi Uno, Hirofumi Makino The Journal of Rheumatology Feb 2024, jrheum.2023-0210; DOI: 10.3899/jrheum.2023-0210

Nov 1, 2023 | accp1.onlinelibrary.wiley.com | Tsutomu Takeuchi |Taisho Pharmaceutical Co |Ltd. Osaka Japan |Yukihiro Chino

Ozoralizumab is a bispecific NANOBODY® compound that binds tumor necrosis factor alpha (TNFα) and human serum albumin (HSA). Ozoralizumab inhibits the TNFα physiological activity while maintaining long-term plasma retention owing to its HSA-binding ability. A population pharmacokinetic (PK) model was developed using data from 494 Japanese patients with rheumatoid arthritis (RA) in phase II/III and phase III trials to assess the effects of potential PK covariates.